Latin America Generic Drugs Market Report and Forecast 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology                  
2    Executive Summary
3    Latin America Generic Drugs Market Overview 
    3.1    Latin America Generic Drugs Market Historical Value (2017-2023) 
    3.2    Latin America Generic Drugs Market Forecast Value (2024-2032)
4    Latin America Generic Drugs Market Landscape*
    4.1    Latin America Generic Drugs: Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Latin America Generic Drugs: Product Landscape
        4.2.1    Analysis by Therapy Area
        4.2.2    Analysis by Route of Administration
        4.2.3    Analysis by Distribution Channels
5    Latin America Generic Drugs Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
        5.2.1    Strengths
        5.2.2    Weaknesses
        5.2.3    Opportunities
        5.2.4    Threats
    5.3    Porter’s Five Forces Model
        5.3.1    Bargaining Power of Suppliers
        5.3.2    Bargaining Power of Buyers
        5.3.3    Threat of New Entrants
        5.3.4    Threat of Substitutes
        5.3.5    Degree of Rivalry
    5.4    Key Demand Indicators 
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends  
    5.7    Value Chain Analysis
6    Latin America Generic Drugs Market Segmentation (2017-2032)
    6.1    Latin America Generic Drugs Market (2017-2032) by Therapy Area
        6.1.1    Market Overview
        6.1.2    Cardiovascular
        6.1.3    Dermatology
        6.1.4    Respiratory
        6.1.5    Oncology
        6.1.6    Rheumatology 
        6.1.7    Others
    6.2    Latin America Generic Drugs Market (2017-2032) by Route of Administration
        6.2.1    Market Overview
        6.2.2    Oral
        6.2.3    Injectables
        6.2.4    Dermal/Topical
        6.2.5    Inhalers
        6.2.6    Others
    6.3    Latin America Generic Drugs Market (2017-2032) by Distribution Channels
        6.3.1    Market Overview
        6.3.2    Hospital Pharmacy
        6.3.3    Retail Pharmacy
        6.3.4    Online Pharmacy
        6.3.5    Others
    6.4    Latin America Generic Drugs Market (2017-2032) by Country
        6.4.1    Market Overview
        6.4.2    Brazil
        6.4.3    Mexico
        6.4.4    Others
7    Brazil Generic  Drugs Market Segmentation (2017-2032)
    7.1    Brazil Generic Drugs Market (2017-2032) by Therapy Area
        7.1.1    Market Overview
        7.1.2    Cardiovascular
        7.1.3    Dermatology
        7.1.4    Respiratory
        7.1.5    Oncology
        7.1.6    Rheumatology 
        7.1.7    Others
    7.2    Brazil Generic Drugs Market (2017-2032) by Route of Administration
        7.2.1    Market Overview
        7.2.2    Oral
        7.2.3    Injectables
        7.2.4    Dermal/Topical
        7.2.5    Inhalers
        7.2.6    Others
8    Mexico Generic Drugs Market Segmentation (2017-2032)
    8.1    Mexico Generic Drugs Market (2017-2032) by Therapy Area
        8.1.1    Market Overview
        8.1.2    Cardiovascular
        8.1.3    Dermatology
        8.1.4    Respiratory
        8.1.5    Oncology
        8.1.6    Rheumatology 
        8.1.7    Others
    8.2    Mexico Generic Drugs Market (2017-2032) by Route of Administration
        8.2.1    Market Overview
        8.2.2    Oral
        8.2.3    Injectables
        8.2.4    Dermal/Topical
        8.2.5    Inhalers
        8.2.6    Others
9    Regulatory Framework
    9.1     Regulatory Overview
        9.1.1    ANVISA Brazil
        9.1.2    COFEPRIS Mexico
10    Patent Analysis
    10.1     Analysis by Type of Patent
    10.2     Analysis by Publication year
    10.3     Analysis by Issuing Authority
    10.4     Analysis by Patent Age
    10.5     Analysis by CPC Analysis
    10.6     Analysis by Patent Valuation 
    10.7     Analysis by Key Players
11    Grants Analysis
    11.1     Analysis by Year
    11.2     Analysis by Amount Awarded
    11.3     Analysis by Issuing Authority
    11.4     Analysis by Grant Housing Material 
    11.5     Analysis by Funding Institute
    11.6     Analysis by Departments
    11.7     Analysis by Recipient Organization 
12    Funding and Investment Analysis
    12.1     Analysis by Funding Instances
    12.2     Analysis by Type of Funding
    12.3     Analysis by Funding Amount
    12.4     Analysis by Leading Players
    12.5     Analysis by Leading Investors
    12.6     Analysis by Geography
13    Partnership and Collaborations Analysis
    13.1     Analysis by Partnership Instances
    13.2     Analysis by Type of Partnership
    13.3     Analysis by Leading Players
    13.4     Analysis by Geography
14    Supplier Landscape
    14.1    Market Share by Top 5 Companies 
    14.2    Teva Pharmaceutical Industries Ltd
        14.2.1    Financial Analysis
        14.2.2    Product Portfolio
        14.2.3    Demographic Reach and Achievements
        14.2.4    Mergers and Acquisitions
        14.2.5    Certifications 
    14.3    Viatris Inc. 
        14.3.1    Financial Analysis
        14.3.2    Product Portfolio
        14.3.3    Demographic Reach and Achievements
        14.3.4    Mergers and Acquisitions
        14.3.5    Certifications 
    14.4    Sun Pharmaceutical Industries Ltd
        14.4.1    Financial Analysis
        14.4.2    Product Portfolio
        14.4.3    Demographic Reach and Achievements
        14.4.4    Mergers and Acquisitions
        14.4.5    Certifications 
    14.5    Lupin
        14.5.1    Financial Analysis
        14.5.2    Product Portfolio
        14.5.3    Demographic Reach and Achievements
        14.5.4    Mergers and Acquisitions
        14.5.5    Certifications 
    14.6    AstraZeneca
        14.6.1    Financial Analysis
        14.6.2    Product Portfolio
        14.6.3    Demographic Reach and Achievements
        14.6.4    Mergers and Acquisitions
        14.6.5    Certifications 
    14.7    Baxter
        14.7.1    Financial Analysis
        14.7.2    Product Portfolio
        14.7.3    Demographic Reach and Achievements
        14.7.4    Mergers and Acquisitions
        14.7.5    Certifications 
    14.8    Takeda Pharmaceutical Company Limited
        14.8.1    Financial Analysis
        14.8.2    Product Portfolio
        14.8.3    Demographic Reach and Achievements
        14.8.4    Mergers and Acquisitions
        14.8.5    Certifications 
    14.9    GSK plc
        14.9.1    Financial Analysis
        14.9.2    Product Portfolio
        14.9.3    Demographic Reach and Achievements
        14.9.4    Mergers and Acquisitions
        14.9.5    Certifications 
    14.10    Bausch + Lomb
        14.10.1    Financial Analysis
        14.10.2    Product Portfolio
        14.10.3    Demographic Reach and Achievements
        14.10.4    Mergers and Acquisitions
        14.10.5    Certifications 
    14.11    Novartis AG
        14.11.1    Financial Analysis
        14.11.2    Product Portfolio
        14.11.3    Demographic Reach and Achievements
        14.11.4    Mergers and Acquisitions
        14.11.5    Certifications 
    14.12    Sanofi
        14.12.1    Financial Analysis
        14.12.2    Product Portfolio
        14.12.3    Demographic Reach and Achievements
        14.12.4    Mergers and Acquisitions
        14.12.5    Certifications 
    14.13    Pfizer Inc.
        14.13.1    Financial Analysis
        14.13.2    Product Portfolio
        14.13.3    Demographic Reach and Achievements
        14.13.4    Mergers and Acquisitions
        14.13.5    Certifications 
    14.14    Fresenius SE & Co. KGaA
        14.14.1    Financial Analysis
        14.14.2    Product Portfolio
        14.14.3    Demographic Reach and Achievements
        14.14.4    Mergers and Acquisitions
        14.14.5    Certifications 
    14.15    Aurobindo Pharma
        14.15.1    Financial Analysis
        14.15.2    Product Portfolio
        14.15.3    Demographic Reach and Achievements
        14.15.4    Mergers and Acquisitions
        14.15.5    Certifications 
15    Latin America  Generic Drugs Market – Distribution Model (Additional Insight)
    15.1     Overview 
    15.2     Potential Distributors 
    15.3     Key Parameters for Distribution Partner Assessment 
16    Key Opinion Leaders (KOL) Insights (Additional Insight)
17    Company Competitiveness Analysis (Additional Insight)
    17.1     Very Small Companies
    17.2     Small Companies
    17.3     Mid-Sized Companies
    17.4     Large Companies
    17.5     Very Large Companies
18    Payment Methods (Additional Insight)
    18.1     Government Funded
    18.2     Private Insurance
    18.3     Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.